Immunological response to boosted PI-containing second line ART after switching for clinical/immunological criteria is comparable to response to first-line in patients with low CD4 counts in Africa.

From:
Department for International Development
Published
1 January 2008
Country:
Uganda, Zimbabwe
Document Type:
Research Paper
Theme:
Health
Authors:
Grosskurth, H., Walker, A.S., Kityo, C., Gilks, C.F., Munderi, P., Ssali, F., Reid, A., Darbyshire, J.H., Chimbetete, C., DART Trial team

Abstract

A group of HIV-infected patients in Uganda and Zimbabwe who did not respond well to first-line antireteoviral therapy (zidovudine/lamivudine plus tenofovir, abacavir or nevirapine) were successfully treated with second-line regimens containing lopinavir/ritonavir – median CD4 cell counts showed a good rate of increase.

Citation

15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, 5-8 February 2008: Abstract 832.

Immunological response to boosted PI-containing second line ART after switching for clinical/immunological criteria is comparable to response to first-line in patients with low CD4 counts in Africa.

Updates to this page

Published 1 January 2008
Contents